| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
As an impurity of lumateperone, this compound does not have a defined therapeutic target. Lumateperone itself targets multiple receptors including serotonin 5-HT2A receptors (antagonist), dopamine D2 receptors (antagonist), and serotonin transporter (SERT) (inhibitor). The impurity may have similar or different receptor binding properties, but its specific pharmacological profile has not been characterized.
|
|---|---|
| ln Vitro |
Specific in vitro activity data for lumateperone-impurity are not available as it is not a therapeutic agent. The compound is used as a reference standard for analytical purposes rather than for pharmacological studies. Its biological activity, if any, has not been characterized.
|
| ln Vivo |
In vivo activity data for lumateperone-impurity are not available as it is not a therapeutic agent. The compound is not used in animal studies or clinical trials. Its primary use is as a reference standard for pharmaceutical quality control.
|
| Enzyme Assay |
Lumateperone-impurity is characterized and quantified using analytical methods such as high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), and mass spectrometry (MS). These methods are used to identify and quantify the impurity in lumateperone drug substance and drug products. The compound serves as a reference standard for method validation and quality control.
|
| Cell Assay |
As a reference standard, lumateperone-impurity is not used in cell-based assays. However, if its biological activity were to be assessed, standard cytotoxicity or receptor binding assays could be employed. The compound's primary use is in analytical method development and quality control, not in biological research.
|
| Animal Protocol |
As a reference standard, lumateperone-impurity is not used in animal studies. Its primary application is in pharmaceutical quality control laboratories for analytical method development and validation. The compound may be used in stability studies to monitor impurity levels in lumateperone drug products.
|
| ADME/Pharmacokinetics |
Lumateperone-impurity has CAS number 313368-85-3. It is a chemical compound identified as an impurity or related substance of lumateperone. The compound is typically stored as a reference standard at -20°C. Detailed physicochemical properties such as molecular weight and formula are not readily available in the public literature. The compound should be handled with appropriate laboratory safety precautions.
|
| Toxicity/Toxicokinetics |
Toxicological data for lumateperone-impurity are limited as it is a reference standard. As an impurity, its levels in pharmaceutical products are controlled to ensure patient safety. The compound's toxicity profile has not been extensively characterized. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
Lumateperone-impurity (CAS# 313368-85-3) is a chemical compound identified as an impurity or related substance of lumateperone (ITI-007), an antipsychotic drug approved for the treatment of schizophrenia. The impurity is used as a reference standard for analytical method development and quality control in pharmaceutical manufacturing. It is not a therapeutic agent and is not used in clinical or biological research.
|
| Molecular Formula |
C14H19N3
|
|---|---|
| Molecular Weight |
229.3208
|
| Exact Mass |
229.158
|
| CAS # |
313368-85-3
|
| PubChem CID |
21302499
|
| Appearance |
Solid Powder
|
| Density |
1.23±0.1g/cm3
|
| Boiling Point |
374.5±42.0°C
|
| LogP |
1.86
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
17
|
| Complexity |
306
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
N12C([H])([H])C([H])([H])N(C([H])([H])[H])C3=C([H])C([H])=C([H])C(=C13)[C@]1([H])C([H])([H])N([H])C([H])([H])C([H])([H])[C@@]21[H]
|
| InChi Key |
QLGUCSLWLPCOTR-RYUDHWBXSA-N
|
| InChi Code |
InChI=1S/C14H19N3/c1-16-7-8-17-12-5-6-15-9-11(12)10-3-2-4-13(16)14(10)17/h2-4,11-12,15H,5-9H2,1H3/t11-,12-/m0/s1
|
| Chemical Name |
(10R,15S)-4-methyl-1,4,12-triazatetracyclo[7.6.1.05,16.010,15]hexadeca-5,7,9(16)-triene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~25 mg/mL (~109.0 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.90 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (10.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3607 mL | 21.8036 mL | 43.6072 mL | |
| 5 mM | 0.8721 mL | 4.3607 mL | 8.7214 mL | |
| 10 mM | 0.4361 mL | 2.1804 mL | 4.3607 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
